Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Jurnal Buana Farma
Daimah Wirdatus Sanaun Harahap
Department of Clinical Pharmacy, Faculty of Health Sciences, Universitas Prima Indonesia, Medan, 20118, Indonesia; PUI Phyto Degenerative & Lifestyle Medicine, Universitas Prima Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
ANALISIS BIAYA TERAPI ASPIRIN DAN CLOPIDOGREL PADA PASIEN STROKE ISKEMIK DI RUMAH SAKIT ROYAL PRIMA TAHUN 2022 – 2025 Nursaima Putri Nasution; Daimah Wirdatus Sanaun Harahap; Astriani Natalia Br Ginting
Jurnal Buana Farma Vol 6 No 1 (2026): Jurnal Buana Farma
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v6i1.1647

Abstract

Ischemic stroke is one of the leading causes of mortality and long-term disability, imposing a substantial economic burden due to high treatment and rehabilitation costs. Antiplatelet therapies such as aspirin and clopidogrel are commonly used for secondary prevention to reduce the risk of recurrent stroke; however, differences in treatment costs require evaluation to support efficient use of healthcare resources. This study aimed to analyze and compare the total cost and cost-effectiveness of aspirin and clopidogrel therapy in patients with ischemic stroke at Royal Prima General Hospital during the period 2022-2025. This study was an observational analytic study with a retrospective design using patients’ medical record data. The analysis was conducted from the hospital perspective by calculating direct medical costs, including drug costs, hospitalization, diagnostic examinations, and medical procedures. Pharmacoeconomic evaluation was performed using the Cost-Effectiveness Analysis (CEA) approach, with cost-effectiveness assessed through the calculation of the Cost-Effectiveness Ratio (CER) based on patients’ clinical outcomes. The results demonstrated differences in total treatment costs between aspirin and clopidogrel therapy, influenced by variations in cost components and patients’ clinical characteristics. In conclusion, cost-effectiveness analysis using CEA and CER can provide a scientific basis for selecting antiplatelet therapy that is rational and cost-efficient in the management of patients with ischemic stroke.
EVALUASI PENGGUNAAN OBAT PADA PASIEN DISPEPSIA MENGGUNAKAN METODE ATC/DDD DI RUMAH SAKIT ROYAL PRIMA TAHUN 2022 Rachel Epifanes Hutabarat; Daimah Wirdatus Sanaun Harahap; Astriani Natalia Br Ginting
Jurnal Buana Farma Vol 6 No 1 (2026): Jurnal Buana Farma
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v6i1.1677

Abstract

Dyspepsia is a common non-communicable disease that requires pharmacotherapy management according to clinical guidelines. Evaluation of drug use can be conducted using the ATC/DDD (Anatomical Therapeutic Chemical/Defined Daily Dose) and DU90% (Drug Utilization 90%) methods to describe prescribing patterns in healthcare facilities. This study aimed to evaluate drug use in dyspepsia patients at Royal Prima Hospital Medan in 2022 using a retrospective descriptive design using medical records of 180 patients from January–December 2022. Drugs were classified based on the WHO 2023 ATC system and analyzed using DDD calculations and the DU90% method. The results showed that four drugs included in the DU90% segment were omeprazole (tablets and injections) and ranitidine (tablets and injections), with a total contribution of 90.4% of the total DDD. The pattern of drug use is dominated by proton pump inhibitors and H₂ receptor antagonists, which are the main therapies in the management of dyspepsia based on the 2022 National Consensus on the Management of Dyspepsia and Helicobacter pylori Infection, so that the distribution of drug use obtained in this study shows compliance with national therapy recommendations.
EFEKTIVITAS DAN BIAYA SEFALOSPORIN PADA PASIEN SIROSIS HEPATIS DENGAN RISIKO SPONTANEOUS BACTERIAL PERITONITIS DI RUMAH SAKIT ROYAL PRIMA PADA TAHUN 2022-2025 Grace Kristin Sonayania Dakhi; Daimah Wirdatus Sanaun Harahap; Astriani Natalia Br Ginting
Jurnal Buana Farma Vol 6 No 1 (2026): Jurnal Buana Farma
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v6i1.1694

Abstract

Hepatic cirrhosis is a chronic liver disease often accompanied by serious complications, one of which is spontaneous bacterial peritonitis (SBP), which plays a significant role in increasing morbidity and mortality. Third-generation cephalosporin antibiotics, such as cefotaxime and ceftriaxone, are widely used as first-line therapy in patients with hepatic cirrhosis at risk of SBP. However, the increasing incidence of bacterial resistance and the high cost of treatment require an evaluation of the clinical effectiveness and cost-efficiency of the therapy provided. This study aims to assess the effectiveness and cost of using cephalosporin antibiotics in patients with hepatic cirrhosis at risk of SBP at Royal Prima Hospital Medan during the period 2022–2025. This study uses a pharmacoeconomic approach in the form of Cost-Effectiveness Analysis (CEA) to assess the cost-effectiveness of cephalosporins based on the relationship between treatment costs and patient clinical outcomes. Cost-effectiveness is assessed through the calculation of the Cost-Effectiveness Ratio (CER). The results show that the characteristics of patients are predominantly male and in the adult to elderly age group. This finding is in line with the epidemiological characteristics of liver cirrhosis which is more common in men, especially due to long-term risk factors such as chronic liver disease and alcohol consumption. The study shows that the analysis of the Cost-Effectiveness Ratio (CER) and Cost-Effectiveness Analysis (CEA) values has a positive and significant effect on total medical costs, which indicates that increasing costs per unit of clinical outcomes will have a direct impact on increasing total treatment costs.
Co-Authors Astriani Natalia Br Ginting Grace Kristin Sonayania Dakhi Nursaima Putri Nasution Rachel Epifanes Hutabarat